Minaxolone

Minaxolone

Minaxolone

Chemical compound


Minaxolone (CCI-12923) is a neuroactive steroid which was developed as a general anesthetic but was withdrawn before registration due to toxicity seen with long-term administration in rats, and hence was never marketed.[1][2][3] It is a positive allosteric modulator of the GABAA receptor,[4] as well as, less potently, a positive allosteric modulator of the glycine receptor.[4][5]

Quick Facts Clinical data, Other names ...

Chemistry

See also


References

  1. Ganellin CR, Triggle DJ (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 1358–. ISBN 978-0-412-46630-4.
  2. Perouansky MA, Hemmings Jr HC (2006). "Intravenous anesthetic agents". In Hemmings HC, Hopkins PM (eds.). Foundations of Anesthesia: Basic Sciences for Clinical Practice. Elsevier Health Sciences. pp. 305–. ISBN 978-0-323-03707-5.
  3. Lambert JJ, Harney SC, Belelli D, Peters JA (2001). "Neurosteroid modulation of recombinant and synaptic GABAA receptor". In Biggio G, Purdy RH (eds.). Neurosteroids and Brain Function. Academic Press. pp. 196–. ISBN 978-0-12-366846-2.
  4. Weir CJ, Ling AT, Belelli D, Wildsmith JA, Peters JA, Lambert JJ (May 2004). "The interaction of anaesthetic steroids with recombinant glycine and GABAA receptors". British Journal of Anaesthesia. 92 (5): 704–711. CiteSeerX 10.1.1.519.3591. doi:10.1093/bja/aeh125. PMID 15033889.

Share this article:

This article uses material from the Wikipedia article Minaxolone, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.